Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%

ELITE PHARMACEUTICALS INC /NV/

2026-Q1 EPS reported -$0.01 revenue$40,211,097

Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.
Operating profits of $21.7M, a 462% increase YoY, driven by sales of lisdexamfetamine products and strong Elite label growth.
Lisdexamfetamine products launched after the prior year Q1, contributing significantly to the top-line expansion.
Company will host a conference call on August 15, 2025 at 11:30 AM EDT to discuss results and provide a business update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.